AI Insight
A clinical trial called NEOPRISM-CRC tested pembrolizumab immunotherapy given before surgery in 32 patients with stage two or three bowel cancer who had a specific genetic profile. Patients received the treatment for up to nine weeks instead of standard post-surgery chemotherapy. After nearly three years of monitoring, none of the 32 patients experienced cancer recurrence, even among those who had residual disease traces after the immunotherapy.
Why it matters
This approach could potentially replace chemotherapy for certain bowel cancer patients, offering a shorter treatment period with fewer side effects and apparently superior long-term outcomes. The results suggest that pre-surgery immunotherapy may provide durable cancer control for patients whose tumors have particular genetic characteristics.
Understand the Science
A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had experienced a cancer recurrence, including those who still had small traces of disease after treatment.
Source: Bowel cancer “melted away” after immunotherapy, then stayed away